VALGANCICLOVIR HYDROCHLORIDE POWDER,

N/A

Manufactured by Ajanta Pharma USA Inc.

24,571 FDA adverse event reports analyzed

Last updated: 2026-04-14

About VALGANCICLOVIR HYDROCHLORIDE POWDER,

VALGANCICLOVIR HYDROCHLORIDE POWDER, is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Ajanta Pharma USA Inc.. The most commonly reported adverse reactions for VALGANCICLOVIR HYDROCHLORIDE POWDER, include OFF LABEL USE, CYTOMEGALOVIRUS INFECTION, DRUG INEFFECTIVE, NEUTROPENIA, LEUKOPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VALGANCICLOVIR HYDROCHLORIDE POWDER,.

Top Adverse Reactions

OFF LABEL USE1,846 reports
CYTOMEGALOVIRUS INFECTION1,197 reports
DRUG INEFFECTIVE1,102 reports
NEUTROPENIA801 reports
LEUKOPENIA661 reports
ACUTE KIDNEY INJURY583 reports
CYTOMEGALOVIRUS VIRAEMIA580 reports
PYREXIA553 reports
DRUG RESISTANCE539 reports
DIARRHOEA534 reports
PRODUCT USE IN UNAPPROVED INDICATION461 reports
PANCYTOPENIA458 reports
TRANSPLANT REJECTION458 reports
THROMBOCYTOPENIA434 reports
ANAEMIA398 reports
RENAL IMPAIRMENT381 reports
CYTOMEGALOVIRUS INFECTION REACTIVATION354 reports
PNEUMONIA338 reports
SEPSIS320 reports
PATHOGEN RESISTANCE308 reports
DRUG INTERACTION296 reports
DEATH285 reports
SEPTIC SHOCK265 reports
NAUSEA257 reports
RESPIRATORY FAILURE254 reports
URINARY TRACT INFECTION246 reports
TOXICITY TO VARIOUS AGENTS232 reports
CONDITION AGGRAVATED230 reports
VOMITING229 reports
BK VIRUS INFECTION225 reports
FEBRILE NEUTROPENIA222 reports
CYTOMEGALOVIRUS COLITIS206 reports
RENAL FAILURE206 reports
BLOOD CREATININE INCREASED204 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME197 reports
DYSPNOEA196 reports
EPSTEIN BARR VIRUS INFECTION196 reports
KIDNEY TRANSPLANT REJECTION195 reports
NEPHROPATHY TOXIC195 reports
ABDOMINAL PAIN193 reports
COVID 19192 reports
MYELOSUPPRESSION187 reports
POLYOMAVIRUS ASSOCIATED NEPHROPATHY182 reports
HYPOTENSION176 reports
POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER174 reports
PRODUCT USE ISSUE174 reports
ASPERGILLUS INFECTION171 reports
INFECTION170 reports
LYMPHOPENIA163 reports
CYTOMEGALOVIRUS CHORIORETINITIS162 reports
FATIGUE159 reports
INTENTIONAL PRODUCT USE ISSUE156 reports
COUGH155 reports
NOCARDIOSIS155 reports
THROMBOTIC MICROANGIOPATHY153 reports
ASTHENIA152 reports
PNEUMOCYSTIS JIROVECII PNEUMONIA152 reports
HEADACHE150 reports
WEIGHT DECREASED148 reports
AGRANULOCYTOSIS143 reports
CANDIDA INFECTION141 reports
HYPERTENSION139 reports
ENTEROCOCCAL INFECTION138 reports
DECREASED APPETITE135 reports
TREMOR135 reports
ESCHERICHIA INFECTION133 reports
IMMUNOSUPPRESSANT DRUG LEVEL INCREASED129 reports
MUCORMYCOSIS127 reports
KLEBSIELLA INFECTION126 reports
BRONCHOPULMONARY ASPERGILLOSIS121 reports
HYPERKALAEMIA121 reports
PSEUDOMONAS INFECTION121 reports
FUNGAL INFECTION116 reports
HAEMOGLOBIN DECREASED116 reports
PNEUMONIA CYTOMEGALOVIRAL115 reports
RASH115 reports
COLITIS114 reports
RENAL TUBULAR NECROSIS113 reports
ENCEPHALITIS CYTOMEGALOVIRUS112 reports
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS111 reports
NO ADVERSE EVENT111 reports
PLEURAL EFFUSION111 reports
TRANSPLANT DYSFUNCTION111 reports
BONE MARROW FAILURE110 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION110 reports
STAPHYLOCOCCAL INFECTION109 reports
CYTOPENIA106 reports
DIABETES MELLITUS98 reports
OEDEMA PERIPHERAL97 reports
RESPIRATORY DISTRESS97 reports
COMPLICATIONS OF TRANSPLANTED KIDNEY95 reports
CYSTITIS HAEMORRHAGIC94 reports
DELAYED GRAFT FUNCTION94 reports
HYPONATRAEMIA94 reports
MALAISE94 reports
POLYOMAVIRUS VIRAEMIA94 reports
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME92 reports
GRAFT VERSUS HOST DISEASE90 reports
WHITE BLOOD CELL COUNT DECREASED90 reports
BACTERIAL INFECTION87 reports

Report Outcomes

Out of 11,599 classified reports for VALGANCICLOVIR HYDROCHLORIDE POWDER,:

Serious 95.3%Non-Serious 4.7%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male5,946 (60.1%)
Female3,929 (39.7%)
Unknown23 (0.2%)

Reports by Age

Age 63293 reports
Age 68252 reports
Age 66235 reports
Age 65227 reports
Age 59225 reports
Age 52214 reports
Age 58207 reports
Age 55205 reports
Age 64197 reports
Age 62194 reports
Age 57193 reports
Age 56184 reports
Age 61183 reports
Age 43180 reports
Age 54180 reports
Age 67175 reports
Age 60174 reports
Age 69170 reports
Age 72169 reports
Age 50168 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with VALGANCICLOVIR HYDROCHLORIDE POWDER,?

This profile reflects 24,571 FDA FAERS reports that mention VALGANCICLOVIR HYDROCHLORIDE POWDER,. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for VALGANCICLOVIR HYDROCHLORIDE POWDER,?

Frequently reported terms in FAERS include OFF LABEL USE, CYTOMEGALOVIRUS INFECTION, DRUG INEFFECTIVE, NEUTROPENIA, LEUKOPENIA, ACUTE KIDNEY INJURY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures VALGANCICLOVIR HYDROCHLORIDE POWDER,?

Labeling and FAERS entries often list Ajanta Pharma USA Inc. in connection with VALGANCICLOVIR HYDROCHLORIDE POWDER,. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.